Association of HIV neutralizing antibody with lower viral load after treatment interruption in a prospective trial (A5170).

TitleAssociation of HIV neutralizing antibody with lower viral load after treatment interruption in a prospective trial (A5170).
Publication TypeJournal Article
Year of Publication2012
AuthorsMcLinden RJ, Paris RM, Polonis VR, Close NC, Su Z, Shikuma CM, Margolis DM, Kim JH
Date Published2012 Jan 2
KeywordsAdult, Antibodies, Neutralizing, Antiretroviral Therapy, Highly Active, CD4 Lymphocyte Count, CD4-Positive T-Lymphocytes, Cohort Studies, Female, HIV Antibodies, HIV Infections, HIV-1, Humans, Male, Neutralization Tests, Prospective Studies, RNA, Viral, Treatment Outcome, Viral Load, Withholding Treatment

OBJECTIVE: We investigated the impact of neutralizing antibodies (NAbs) on CD4 T-cell count and viral load in a cohort of HAART recipients who underwent extended structured treatment interruption.

DESIGN: Substudy of NAb in the AIDS Clinical Trials Group 5170 trial.

METHODS: Early plasma samples from 50 volunteers who discontinued HAART were evaluated in a peripheral blood mononuclear cell-based neutralization assay against a panel of four subtype B primary isolates.

RESULTS: We found that high-titer (90% inhibitory dose > 500) NAb against two or more isolates was associated with reduced viral load (P = 0.003 at 12-week posttreatment interruption). This effect faded with time, losing significance (P = 0.161) by study conclusion. Participants possessing the highest NAb levels against individual isolates appeared more likely to have lower viral loads with the association gaining significance against the R5-tropic primary isolate US1 (P = 0.005). There was no association between broader neutralization and CD4 T-cell slope over time.

CONCLUSION: The data suggest that high-titer NAb responses at the time of treatment interruption are associated with reduced viral load over time, but not CD4(+) T-cell decline.

Alternate JournalAIDS
PubMed ID21971356
Grant ListP30 AI050410 / AI / NIAID NIH HHS / United States
RR03061-18 / RR / NCRR NIH HHS / United States